Rob O'Brien in action at a March 8 Employers Health conference. With payers creating access barriers to many new therapies (specialty meds, here's looking at you), influencing employers' coverage decisions is a top priority for many drug companies. It's a tricky proposition, though.
read full article ›An important topic given the number of drugs that require a diagnostic for use. @Real Endpoints will dive deeper into this topic at BIO in June, just fyi.
read full article ›